The Food and Drug Administration (FDA) approved the second RSV vaccine ever: Pfizer’s ABRYSVO, for adults over age 60.
Why it matters: RSV is a highly contagious upper respiratory disease that’s especially dangerous for the oldest and youngest age groups. RSV leads to approximately 60,000-120,000 hospitalizations and 6,000-10,000 deaths among adults 65 and over.
From zero to two in one month: This is the second-ever RSV vaccine after the FDA approved GSK’s Arexvy, also for adults over 60, on May 3.
Ready for fall RSV season: The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices meets June 21 to discuss recommendations for RSV vaccines for older adults. “Pending the outcome of this meeting, Pfizer anticipates supply availability in Q3 2023 ahead of the anticipated RSV season this fall,” Pfizer said.
Kids are next: With children being another high-risk group, Pfizer has already requested market approval for a maternal RSV vaccine to protect unborn infants. FDA is expected to decide on that vaccine candidate by August.
More RSV shots coming: Several other RSV immunizations are under development, reports Bio.News.
Read more about Pfizer’s RSV vaccine in Bio.News.